Role of adenosine as an adjunct therapy in the prevention and treatment of no-reflow phenomenon in acute myocardial infarction with ST segment elevation: Review of the current data

Kardiologia Polska

Volumn 71, Issue 2, 2013, Pages 115-120

  Grygier, Marek ^a   Araszkiewicz, Aleksander ^a   Lesiak, MacIej ^a   Grajek, Stefan ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; PLACEBO;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ELECTROCARDIOGRAM; HEART INFARCTION SIZE; HEART MUSCLE REPERFUSION; HUMAN; NO REFLOW PHENOMENON; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; REVIEW; ST SEGMENT ELEVATION; TISSUE PERFUSION;

EID: 84874274107     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: 10.5603/KP.2013.0002     Document Type: Review

References (34)

1. Gibson CM, Schoming A. Coronary and myocardial angiography. Angiographic assessment of both epicardial and myocardial perfusion. Circulation, 2004; 109: 3096-3105.
2. Jaffe R, Charron T, Puley G et al. Microvascular obstruction and the no-refow phenomenon after percutaneous coronary intervention. Circulation, 2008; 117: 3152-3156.
3. Ndrepepa G, Tiroch K, Fusaro M et al. 5-year prognostic value of no-refow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol, 2010; 55: 2383-2389.
4. Rezkalla SH, Kloner RA. Coronary no refow phenomenon: from the experimental laboratory to the cardiac catherization laboratory. Catheter Cardiovasc Interv, 2008; 72: 950-957.
5. Klein LW, Kern MJ, Berger P et al. Society of Cardiac Angiogra-phy and Interventions: suggested management of the no-refow phenomenon in the cardiac catherization laboratory. Catheter Cardiovasc Interv, 2003; 60: 194-201.
6. Moens AL, Claeys MJ, Timmermans JP, Vrints CJ. Myocardial ischemia/reperfusion injury, a clinical view on a complex patho-physiological process. Int J Cardiol, 2005; 100: 179-190.
7. van 't Hof AW, Liem A, de Boer MJ, Zijlstra F. Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Zwolle Myocardial infarction Study Group. Lancet, 1997; 350: 615-619.
8. Brodie BR, Stuckey TD, Hansen C et al. Relation between electrocardiographic ST-segment resolution and early and late outcomes after primary percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol, 2005; 95: 343-348.
9. Gibson CM, Cannon CP, Daley WL et al. TIMI frame count: a quantitative method of assessing coronary artery fow. Circulation, 1996; 93: 879-888.
10. Van't Hof AW, Liem A, Suryapranata H et al. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial infarction Study Group. Circulation, 1998; 97: 2302-2306.
11. Araszkiewicz A, Grajek S, Lesiak M et al. Effect of impaired myocardial reperfusion on left ventricular remodelling in patients with anterior wall myocardial infarction treated with primary coronary intervention. Am J Cardiol, 2006; 98: 725-728.
12. Forman MB, Stone GW, Jackson EK. Role of adenosine as adjunc-tive therapy in acute myocardial infarction. Cardiovasc Drug Rev, 2006; 24: 116-147.
13. Brosh D, Asali AR, Mayer A et al. Effect of no-refow during primary percutaneous intervention for acute myocardial infarction on six-month mortality. Am J Cardiol, 2007; 99: 442-445.
14. Kloner RA. No-refow phenomenon: maintaining vascular integrity. J Cardiovasc Pharmacol Therap, 2011; 16: 244-250.
15. Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-refow in humans. J Am Coll Cardiol, 2009; 54: 281-292.
16. Montalescot G, Barragan P, Wittenberg O et al. Platelet glycopro-tein IIb/IIIa inhibition with coronary stenting for acute myocar-dial infarction. N Engl J Med, 2001; 344: 1895-1903.
17. Svilaas T, Vlaar PJ, van der Horst IC et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med, 2008; 358: 557-567.
18. Stone GW, Webb J, Cox A et al. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized control trial. JAMA, 2005; 293: 1063-1072.
19. Olafsson B, Forman MB, Puett DW et al. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-refow phenomenon. Circulation, 1997; 76: 1135-1145.
20. Babbitt DG, Virmani R, Vildibill HD et al. Intracoronary ad-enosine administration during reperfusion following 3 hours of ischemia: effects on infarct size, ventricular function, and regional myocardial blood fow. Am Heart J, 1990; 120: 808-818.
21. Garratt KN, Holmes DR Jr, Molina-Viamonte V et al. Intravenous adenosine and lidocaine in patients with acute myocardial infarction. Am Heart J, 1998; 136: 196-204.
22. Claeys MJ, Bosmans J, De Ceuninck M et al. Effect of intrac-oronary adenosine infusion during coronary intervention on myocardial reperfusion injury in patients with acute myocardial infarction. Am J Cardiol, 2004; 94: 9-13.
23. Marzilli M, Orsini E, Marraccini P, Testa R. Benefcial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation, 2000; 101: 2154-2159.
24. Mahaffey KW, Puma JA, Barbagelata NA et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol, 1999; 34: 1711-1720.
25. Ross AM, Gibbons RJ, Stone GW et al. AMISTAD-II Investigators. A randomized, double-blinded, placebo controlled mul-ticenter trial of adenosine as an adjunct to reperfusion in the treatment acute myocardial infarction (AMISTAD-2). J Am Coll Cardiol, 2005; 45: 1775-1780.
26. Kloner RA, Forman MB, Gibbons RJ et al. Impact of time to therapy and reperfusion modality on the effcacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J, 2006: 27: 2400-2405.
27. Quintana M, Hjemdahl P, Sollevi A et al. ATTACC investigators. Left ventricular function and cardiovascular events following adjuvant therapy with adenosine in acute myocardial infarction treated with thrombolysis, results of the ATTenuation by Adenosine of Cardiac Complications (ATTACC) study. Eur J Clin Pharmacol, 2003; 59: 1-9.
28. Stoel MG, Marques KM, de Cock CC et al. High-dose adenosine for suboptimal myocardial reperfusion after primary PCI: a randomized placebo controlled pilot study. Catheter Cardiovasc Interv, 2008; 71: 283-289.
29. Fokkema ML, Vlaar P, Vogelzang M et al. Effect of high-dose in-tracoronary adenosine administration during percutaneous coronary intervention in acute myocardial infarction-a ran domized controlled trial. Circ Cardiovasc Interv, 2009; 2: 323-329.
30. Sakuma T, Motoda C, Tokuyama T et al. Exogenous adenosine triphosphate disodium administration during primary percutaneous coronary intervention reduces no-refow and preserves left ventricular function in patients with acute anterior myocardial infarction: a study using myocardial contrast echocardiography. Int J Cardiol, 2010; 140: 200-209.
31. Desemet W, Bogaert J, Dubois C et al. High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction. Eur Heart J, 2011; 32: 867-877.
32. Grygier M, Araszkiewicz A, Lesiak M et al. New method of intracoronary adenosine injection to prevent of microvascular reperfusion injury in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol, 2011; 107: 1131-1135.
33. Wang J, Chen Y, Zhi G et al. Benefcial effect of adenosine on myocardial perfusion treated with primary percutaneous coronary intervention for acute myocardial infarction. Clin Exp Pharmacol Physiol, 2012; 39: 247-252.
34. Navarese EP, Buffon A, Andreotti F et al. Adenosine improves post-procedural coronary fow but not clinical outcomes in patients with acute coronary syndrome: a meta-analysis of randomized trials. Atherosclerosis, 2012; 222: 1-7.